Among four patients without recurrent FSGS, two had extensive effacement (FAC assay 87% (NPSH2 mutation) and 105%), one showed partial effacement (FAC assay 72%, PLCε1 mutation) and one showed no effacement (FAC assay 68%, INF2 mutation). This evidence concerns the gene PLCE1 and focal segmental glomerulosclerosis.